Carregant...
Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens
Hypersensitivity reactions (HSRs) to paclitaxel are frequently encountered in patients receiving this antitumour drug. Administration of histamine H1- and H2-receptor antagonists and corticosteroids has been shown to reduce significantly the risk of developing an HSR in patients receiving taxanes. I...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group
2004
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2409560/ https://ncbi.nlm.nih.gov/pubmed/14974481 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601303 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|